BioCentury
ARTICLE | Company News

MorphoSys acquires Lanthio

May 8, 2015 2:17 AM UTC

MorphoSys AG (Xetra:MOR; Pink:MPSYF) said it will acquire all the shares it does not already own of Lanthio Pharma B.V. (Groningen, the Netherlands) for EUR 20 million ($22.3 million). MorphoSys, which invested in Lanthio's series A round in 2012, had owned just under 20% of the company (see BioCentury, Dec. 10, 2012).

Lanthio's portfolio of lantipeptides includes lead candidate LP2, a selective angiotensin II type 2 (AT2) receptor ( ATGR2) agonist in preclinical development to treat diabetic nephropathy and fibrotic diseases. MorphoSys will rename the compound MOR107 and expects to begin clinical studies in 2016. ...